Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Mendelsohn

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Cancer Immunology, Immunotherapy : CII|April 18, 2003
Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinicJohn Mendelsohn
Journal of the National Cancer Institute|August 10, 2010
Shaking up cancer clinical trials: an interview with John Mendelsohn, M.D., by Joanne NicholasJohn Mendelsohn
Cancer Research|September 17, 2016
Commentary on "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" (A Follow Up)John Mendelsohn
Science Translational Medicine|March 25, 2011
A national cancer clinical trials system for targeted therapiesJohn Mendelsohn
Transactions of the American Clinical and Climatological Association|October 25, 2006
EGF receptors as a target for cancer therapyJohn Mendelsohn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Personalizing oncology: perspectives and prospectsJohn Mendelsohn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2002
Targeting the epidermal growth factor receptor for cancer therapyJohn Mendelsohn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancerJohn Mendelsohn, Jose Baselga
Proceedings of the National Academy of Sciences of the United States of America|November 9, 2006
Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?Massimo Cristofanilli, John Mendelsohn
Seminars in Oncology|August 8, 2006
Epidermal growth factor receptor targeting in cancerJohn Mendelsohn, Jose Baselga
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Cancer Immunology, Immunotherapy : CII|April 18, 2003
Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinicJohn Mendelsohn
Journal of the National Cancer Institute|August 10, 2010
Shaking up cancer clinical trials: an interview with John Mendelsohn, M.D., by Joanne NicholasJohn Mendelsohn
Cancer Research|September 17, 2016
Commentary on "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" (A Follow Up)John Mendelsohn
Science Translational Medicine|March 25, 2011
A national cancer clinical trials system for targeted therapiesJohn Mendelsohn
Transactions of the American Clinical and Climatological Association|October 25, 2006
EGF receptors as a target for cancer therapyJohn Mendelsohn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Personalizing oncology: perspectives and prospectsJohn Mendelsohn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2002
Targeting the epidermal growth factor receptor for cancer therapyJohn Mendelsohn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancerJohn Mendelsohn, Jose Baselga
Proceedings of the National Academy of Sciences of the United States of America|November 9, 2006
Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?Massimo Cristofanilli, John Mendelsohn
Seminars in Oncology|August 8, 2006
Epidermal growth factor receptor targeting in cancerJohn Mendelsohn, Jose Baselga
Pageof 7